OXFORD BIOTHERAPEUTICS LTD.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 17238
 
  
 
C07K PEPTIDES 13123
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 5201
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 148

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2016/0069,880 PROTEINSSep 11, 15Mar 10, 16[G01N, C07K]
2015/0297,743 LY75 AS CANCER THERAPEUTIC AND DIAGNOSTIC TARGETNov 06, 13Oct 22, 15[A61K, G01N]
2015/0210,770 THERAPEUTIC AND DIAGNOSTIC TARGETJul 31, 13Jul 30, 15[A61K, G01N, C07K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9903872 Identification of protein associated with hepatocellular carcinoma, gliobastoma and lung cancerSep 10, 15Feb 27, 18[A61K, G01N, C07K]
9732160 Methods of treating acute myeloid leukemia with antibodies to bone marrow stromal antigen 1Sep 23, 15Aug 15, 17[A61K, C07K]
9447178 Therapeutic and diagnostic targetJun 28, 12Sep 20, 16[A61K, C12Q, G01N, C07K]
9228023 Anti-ROR1 antibodies and methods of use for treatment of cancerOct 03, 11Jan 05, 16[A61K, A61P, C07K]
9200055 ProteinAug 26, 09Dec 01, 15[G01N, C07K]
9181339 Antibodies specific to cadherin-17Apr 20, 10Nov 10, 15[A61K, C07K]
9175092 Antibodies to bone marrow stromal antigen 1Mar 15, 13Nov 03, 15[A61K, C07K]
8420084 Fully human antibodies specific to CADM1Mar 05, 10Apr 16, 13[A61K, C07K]
8420091 Matriptase protein and uses thereofFeb 07, 10Apr 16, 13[A61K]
8084034 ProteinsAug 26, 09Dec 27, 11[A61K]

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2016/0175,437 PROTEINAbandonedNov 24, 15Jun 23, 16[A61K, C12Q, G01N, C07K]
2016/0039,933 ANTIBODIES SPECIFIC TO CADHERIN-17AbandonedOct 05, 15Feb 11, 16[A61K, C07K]
2016/0002,351 INACTIVE N-ACETYLATED-ALPHA-LINKED ACIDIC DIPEPTIDASE-LIKE PROTEIN 2 (NAALADL2) AS A THERAPEUTIC AND DIAGNOSTIC TARGETAbandonedFeb 24, 14Jan 07, 16[A61K, G01N, C07K]
2015/0093,392 ANTIBODIESAbandonedNov 20, 14Apr 02, 15[G01N, C07K]
8652478 Method for treating cancer by administering antibody to ephrin type-A receptor 7ExpiredJun 09, 09Feb 18, 14[A61K]
2014/0024,048 PROTEINAbandonedAug 09, 13Jan 23, 14[G01N]
2013/0259,878 ANTIBODIESAbandonedOct 19, 11Oct 03, 13[C07K]
8540998 Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agentsExpiredDec 24, 08Sep 24, 13[A61K]
8535677 Antibody drug conjugate treatment of colorectal cancerExpiredDec 01, 10Sep 17, 13[A61K]
2013/0156,788 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1AbandonedDec 27, 12Jun 20, 13[C07K]
2013/0136,689 PROTEINSAbandonedDec 13, 12May 30, 13[G01N]
2012/0282,177 ROR1 as Therapeutic and Diagnostic TargetAbandonedNov 02, 10Nov 08, 12[A61K, C12P, C12N, G01N, C07K]
2012/0231,004 ANTIBODIESAbandonedOct 13, 10Sep 13, 12[A61K, A61P, C07K]
2012/0058,131 PTA089 PROTEINAbandonedJan 21, 10Mar 08, 12[A61K, C12Q, G01N, A61P, C07K]
2011/0229,480 PTA072 PROTEINAbandonedSep 03, 09Sep 22, 11[A61K, C07H, C12Q, C12N, G01N, A61P, C07K]
2011/0110,859 ProteinAbandonedDec 08, 10May 12, 11[A61K, C07H, C12Q, G01N, A61P]
2010/0284,918 PROTEINAbandonedOct 03, 08Nov 11, 10[A61K, C12Q, G01N, A61P]
2010/0098,627 PROTEINSAbandonedAug 26, 09Apr 22, 10[A61K, G01N, A61P]
2010/0098,628 PROTEINSAbandonedAug 26, 09Apr 22, 10[A61K, C12Q, A61P]
2009/0238,833 PROTEINAbandonedFeb 27, 09Sep 24, 09[A61K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.